Juvmo (copackaged) is a drug owned by Abbvie Inc. It is protected by 4 US drug patents filed in 2026 out of which none have expired yet. Juvmo (Copackaged)'s patents will be open to challenges from 25 September, 2030. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 23, 2034. Details of Juvmo (copackaged)'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9107923 | Heteroaromatic Compounds And Their Use As Dopamine D1 Ligands |
Jun, 2034
(7 years from now) | Active |
| US9527831 | Heteroaromatic Compounds And Their Use As Dopamine D1 Ligands |
Jun, 2034
(7 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10093655 | Heteroaromatic Compounds And Their Use As Dopamine D1 Ligands |
Jun, 2034
(7 years from now) | Active |
| US10421744 | Heteroaromatic Compounds And Their Use As Dopamine D1 Ligands |
Jun, 2034
(7 years from now) | Active |
FDA has granted several exclusivities to Juvmo (copackaged). Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Juvmo (copackaged), regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Juvmo (copackaged).
Exclusivity Information
Juvmo (copackaged) holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Juvmo (copackaged)'s exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2031 |
US patents provide insights into the exclusivity only within the United States, but
Juvmo (copackaged) is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Juvmo (copackaged)'s family patents as well as insights into
ongoing legal events
on those patents.
Juvmo (copackaged)'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Juvmo (copackaged)'s generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 23, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Juvmo (copackaged) Generics:
There are no approved generic versions for Juvmo (copackaged) as of now.
Alternative Brands for Juvmo (copackaged)
There are several other brand drugs in the same treatment category and using the same active ingredient (Tavapadon) as Juvmo (copackaged). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch |
| |||||||||||||||
| Boehringer Ingelheim |
| |||||||||||||||
| Impax |
| |||||||||||||||
| Orion Pharma |
| |||||||||||||||
| Supernus Pharms |
| |||||||||||||||
| Teva |
| |||||||||||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Tavapadon. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie |
|
About Juvmo (copackaged)
Juvmo (Copackaged) is a drug owned by Abbvie Inc. Juvmo (Copackaged) uses Tavapadon as an active ingredient. Juvmo (Copackaged) was launched by Abbvie in 2026.
Approval Date:
Juvmo (copackaged) was approved by FDA for market use on 25 September, 2026.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Juvmo (copackaged) is 25 September, 2026, its NCE-1 date is estimated to be 25 September, 2030.
Active Ingredient:
Juvmo (copackaged) uses Tavapadon as the active ingredient. Check out other Drugs and Companies using Tavapadon ingredient
Dosage:
Juvmo (copackaged) is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.25MG;1MG | TABLET | Prescription | ORAL |
